



A Comparative Analysis of Patients' Medicine Price in a Public Tertiary Hospital and Private Retail Community Pharmacy in a Rural Nigerian Community

Roland Nnaemeka Okoro^{1*} and Chijioke Nmekwa²

¹*Department of Clinical Pharmacy and Pharmacy Administration, Faculty of Pharmacy, University of Maiduguri, P.M.B 1069, Maiduguri, Borno State, Nigeria.*

²*Department of Pharmacy, University of Nigeria Teaching Hospital, Ituku-Ozalla, Enugu, Enugu State, Nigeria.*

Authors' contributions

This work was carried out in collaboration between both authors. Author RNO designed the study, performed the statistical analysis, wrote the protocol and wrote the first draft of the manuscript. Authors RNO and CN managed the analyses of the study. Author RNO managed the literature searches. Both authors read and approved the final manuscript.

Article Information

DOI: 10.9734/AJRIMPS/2018/41764

Editor(s):

(1) Davina Hijam, Professor, Department of Biochemistry, Regional Institute of Medical Sciences, India.

Reviewers:

(1) Marcelino José Jorge, Evandro Chagas National Institute of Infectious Diseases, Brazil.

(2) Syed Umer Jan, University of Balochistan, Pakistan.

(3) Bogumil E. Brycki, Adam Mickiewicz University, Poland.

Complete Peer review History: <http://www.sciencedomain.org/review-history/24885>

Original Research Article

Received 12th March 2018

Accepted 22nd May 2018

Published 31st May 2018

ABSTRACT

Background: One-third of the world's population lacks access to essential medicines and price of medicine is considered one of the most important obstacles to access. Improving access to quality medicines and treatment is currently the most important strategy to reduce disability and death from many diseases.

Aim: The objective of this study was to compare the patient prices of medicines in a public teaching hospital and a private retail community pharmacy in a rural Nigerian community.

Methods: A cross-sectional prospective survey was conducted in a public tertiary hospital

*Corresponding author: E-mail: orolandn@gmail.com;

pharmacy and private retail community pharmacy in Nigeria. The price was recorded for the list of medicines commonly available in those pharmacies. A total of 30 pharmaceuticals products were selected for data collection. The price was recorded based on the hospital price list and price reported by surrogate customers that visited community pharmacy respectively. Median prices of the two groups were compared with Mann-Whitney test at 95% Confidence interval.

Results: Out of 30 pharmaceutical products selected for survey, only 19 (63.30%) matched pair were recorded. Highest price variation of 80.00% was recorded for metformin 500mg tab, whereas lowest price variation negative of 2.60% was recorded for amoxicillin+clavulanic acid 625mg tab in public pharmacy. The median price of the basket of medicines surveyed did not vary significantly between public pharmacy and private retail community pharmacy ($P > 0.05$).

Conclusion: The patients' medicine prices found in the public hospital and community pharmacy were almost identical. Therefore, the Nigerian government through its ministry of health should play proactive roles to keep the patient prices of medicines much lower in the public hospitals than what is obtained in the private retail community pharmacies.

Keywords: Medicines; Nigeria; price variation; private retail pharmacy; public hospital pharmacy.

1. INTRODUCTION

One-third of the world's population lacks access to essential medicines; in the poorest parts of Africa and Asia this figure rises to one-half [1]. Medicines account for 20–60% of health spending in developing countries [2-4], and up to 90% of the population in developing countries purchase medicines through out-of-pocket payments [5-8], which has impoverishing effects on the people [9]. This means that access to treatment is much dependent on the availability of affordable medicines. The price of medicine is considered one of the most important obstacles to access [10]. Access to medicines is an important health policy issue. Inefficient or expensive procurement and distribution increases the final price to patient, reducing volume sales and hurting family finances in the largely out-of-pocket payments for medicines.

The expenditure on medicines constitutes a major proportion of healthcare costs in Nigeria despite the fact that one of the objectives of Nigerian national drug policy is to ensure access to safe, effective, affordable and good quality drugs at all levels of healthcare on the basis of health needs [11]. The Nigerian health care system is organized into primary, secondary and tertiary healthcare levels. The Local Government Areas (LGAs) are responsible for primary health care; the State Governments are responsible for providing secondary care while the Federal Government is responsible for policy development, regulation, overall stewardship and providing tertiary care [12]. Nigeria is a middle-income country with ineffective public health system; it is facing a rapid rise in drug costs. Public sector procurement in Nigeria is

decentralized [13], only medication for HIV, malaria and tuberculosis are centrally procured. Most medicines are procured and stored by the individual health care institutions [14].

There are no legal or regulatory provisions affecting pricing of medicines in the country [13]. Medicine prices are determined by free-market economics, without any control by government. Regulations do not exist mandating that retail medicine price information should be publicly accessible [13].

However, the enjoyment of health is one of the fundamental rights of every human being. Access to essential medicines as part of the fulfillment of the right to health, is recognized in the constitution or national legislation [13]. Therefore, public health facilities are expected to provide medicines free or at low and affordable prices to majority of Nigerians. Improving access to quality treatment is currently the most important strategy to reduce disability and death from many diseases. More generally, ensuring access to effective treatment is a high priority issue for international public health.

Majority of Nigerians live below poverty line of less than 1 USD a day [15]. The national health insurance scheme, which is a viable leeway for people to access health services, still covers only 4% of Nigerian population (only those working for the government and organized private sector) [16]. From the foregoing, it is evident that Nigerian patients are having difficulties accessing the medicines they need and that cost is an important factor due to high out-of-pockets spending on medicines. Therefore, issues concerning prices of medicines are keys to

improving access to essential medicines in Nigeria.

Following observations that the cost of medicines has been rising faster than overall consumer prices in a number of countries worldwide, World Health Organization (WHO) and Health Action International (HAI) sponsored a national medicines price survey in 2004 in eight African countries including Nigeria, in order to determine the prices people pay for their medicines [17]. After over a decade, there is a need for situation analysis of prices of medicines at individual healthcare facility level to gain insight into prices people pay for their medicines. Therefore, this study aimed to compare the prices of medicines in a public hospital pharmacy and private retail pharmacy in a rural community of South Eastern Nigeria. The medicine prices survey is an effective tool for identifying how patients are charged for medicines and to inform policy interventions relating to medicine pricing.

2. METHODS

2.1 Study Design and Setting

A cross-sectional, prospective study was conducted in the University of Nigeria Teaching Hospital (UNTH) and a private retail community pharmacy within 200m from the main gate of the hospital in Ituku-Ozalla community, Nkanu West of Enugu State, Nigeria in October 2014. UNTH is a 500 bedded reference tertiary health facility in Enugu State, South East Nigeria. It serves over the three million citizens of Enugu State and

is a referral centre to the neighbouring South Eastern States of Nigeria.

2.2 Sampling

The tertiary hospital was purposively selected for this study because it is the only specialized hospital in Ituku-Ozalla. One out of the only two community pharmacies that are closest to the hospital at the time of the study was randomly selected by simple balloting.

2.3 Data Collection

A systematic data collection form was developed and pretested at National Health Insurance Scheme pharmacy outlet of the public hospital. A total of 30 pharmaceutical products were selected from three drug classes (anti-hypertensives, anti-diabetes, and anti-infectives) for the survey based on the disease burden of the hospital according to an earlier study [18]. The prices of medicines from the hospital pharmacy were collected from the hospital general outpatients medicine price list, whereas that of the private retail pharmacy was collected by trained surrogate customers by asking the retail person in the pharmacy. Four surrogate customers were recruited to get the accurate retail price of medicines because private pharmacies are reluctant to tell the price of medicines in Nigeria. The unit retail price of the same medicine with the same brand name and the same dose was collected from hospital pharmacy and private pharmacy on the same day.



Fig. 1. The study area

2.4 Data Analysis

Only the 19 matched pairs of the surveyed medicines available in both hospital pharmacy and retail pharmacy were included in the analysis. The matched pairs of medicines are in the Nigerian essential medicine list [19].

A detailed method for calculating price variation and availability of drugs is described elsewhere [20]. Price variation was expressed as the difference in price of medicines in private retail pharmacy to public pharmacy divided by the price of medicine in public pharmacy (expressed as percentage):

Percentage Price Variation =

$$\frac{\text{Price of medicine in private pharmacy} - \text{Price of medicine in public pharmacy}}{\text{Price of medicine in public pharmacy}} \times 100$$

The exchange rate on the first day of data collection was NGN1.00 = US\$ 0.00613

2.5 Statistical Analysis

Microsoft Excel 2007 and Statistical Package for Social Sciences (SPSS) version 21 were used for data entry and analysis. Price variations of 19 medicines common at public hospital pharmacy and private retail pharmacy were calculated. Data was presented as percentage, median, and percentiles. The overall price of medicines at hospital pharmacy and private retail pharmacy was compared with Mann-Whitney U test at 95% confidence interval (CI).

3. RESULTS

Out of 30 pharmaceutical products selected for survey, only 19 (63.3%) matched pair were recorded in both studied hospital and community pharmacy. The price variation in the two locations is shown in the table below. Highest price variation of 80.00% was recorded for Metformin 500 mg, whereas lowest price

Table 1. Variability of the price of the same medicine across public hospital and community pharmacy

Medicines generic names	Medicines trade names	Public hospital	Community pharmacy	Price variation
		unit price NGN(US\$)	unit price NGN(US\$)	%
Metformin 500 mg tab	Forbetic® by Swipha	5.00(0.03)	9.00(0.06)	80.00
Glibenclamide 5 mg tab	Clamids® by Hovid	5.00(0.03)	8.00(0.05)	60.00
Atenolol 50 mg tab	Atenolol by Teva	10.00(0.06)	10.00(0.06)	0.00
Amlodipine 5 mg tab	Amlovar® by Neimeth	40.00(0.25)	40.00(0.25)	0.00
Nifedipine (Sustained-release) 20 mg tab	Medipine® by Evans	10.00(0.06)	10.00(0.06)	0.00
Hydrochlorothiazide 50 mg+ Amiloride 5 mg tab	Normoretic® by Neimeth	6.50(0.04)	9.00(0.06)	38.46
Frusemide 40 mg tab	Renix® by Reals	5.00(0.03)	5.00(0.03)	0.00
Spirolactone 25 mg tab	Spirotac® by Hovid	15.00(0.09)	10.00(0.06)	-33.33
Methyldopa 250 mg tab	Celodopa® by JB Pharma	10.00(0.06)	9.00(0.06)	-10.00
Lisinopril 5 mg tab	Lisinopril by Teva	15.00(0.09)	17.86(0.11)	19.07
Ampicillin + Cloxacillin 500 mg cap	Emclox® by Emzor	10.00(0.06)	10.00(0.06)	0.00
Amoxicillin 500 mg cap	Moxiten® by Micro Labs	12.00(0.07)	10.00(0.06)	-16.67
Amoxicillin + Clavulanic acid 625 mg cap/tab	Amovin® by Evans	110.00(0.67)	107.14(0.66)	-2.60
Cefuroxime 500 mg tab	Cefunat® by Evans	135.00(0.83)	142.86(0.88)	5.82
Ciprofloxacin 500 mg tab	Cipro-J® by Juhel	20.00(0.12)	17.86(0.11)	-10.70
Co-trimoxazole 480 mg tab	Emtrin® by Emzor	3.50(0.02)	3.00(0.02)	-14.29
Doxycycline 100 mg cap	Doxycline by Mekophar	8.00(0.05)	10.00(0.06)	25.00
Erythromycin 500 mg tab	Erythin® by ACI	15.00(0.09)	25.00(0.15)	66.67
Metronidazole 400 mg tab	Loxagyl® by May & Baker	5.00(0.03)	5.00(0.03)	0.00
	Median	10(0.06)	10(0.06)	0.00
	25 TH Percentile	5.00(0.03)	9.00(0.06)	80.00
	75 TH Percentile	15.00(0.09)	17.86(0.11)	19.07

variation negative of 2.60% was recorded for Amoxicillin+Clavulanic acid 625 mg tab in public pharmacy. No price variation was found for tablets of Atenolol 50 mg, Amlodipine 5 mg, Nifedipine 20 mg, Frusemide 40mg, Ampiclox+Cloxacillin 500 mg, and Metronidazole 400 mg. However, prices of Spironolactone 25 mg, Methyldapa 250 mg, Amoxicillin 500 mg, Amoxicillin+Clavulanic acid 625 mg, Ciprofloxacin 500 mg, and Co-trimoxazole 480 mg were higher in public pharmacy compare to private retail pharmacy. It was observed that the median price of the basket of medicines surveyed did not vary in public pharmacy and private retail pharmacy ($P > 0.05$).

4. DISCUSSION

This study revealed no overall significant variation in prices of medicines in public hospital and private retail community pharmacy in the studied area. It was found that patients' medicine prices in the public hospital pharmacy were almost identical to prices in the private retail pharmacy. This makes one to wonder about the purposes of the public sector pharmacy in offering the most affordable opportunities in accessibility of medicines by most of the Nigerians. The findings of this study are consistent with the previous studies done in Nigeria and Indonesia [17,21]. In contrast, significant medicine price variation between public hospitals and private pharmacies has been reported in other developing countries such as Nepal, Ghana, Ethiopia, Malaysia, and Peru [22,23-26]. A Plausible reason for the finding of the current study in the tertiary hospital might be due to several causes such as the inefficient procurement methods and excessive mark-ups. Pooling procurement, using open competitive tendering, price information and price negotiations [27], and low mark-up are all well known means of ensuring affordable pricing in the public healthcare facilities. However, in most public health care facilities in Nigeria, procurement is decentralized to the facility level making it impossible for the earlier mentioned strategies to be employed. Another reason may be due to that fact that the hospital studied still run revolving drug funds (DRF) scheme. The DRF managers run the scheme as a purely profit oriented venture. They include mark-ups to prevent depletion of the capital and to ensure provision for depreciation due to inflation [17]. Increases in the prices of medicines result in a decrease in the affordability of medicines. This has led to and continues to lead to negative

health outcomes such as patient's dissatisfaction, increased morbidity and mortality arising from the use of and change to different medicines, or to patients forgoing some medicines due to the increased prices [28].

Astronomical drug prices are making expensive medicines inaccessible to patients and in the process may be killing them [29]. Therefore, it is the responsibility of every nation to provide quality and affordable healthcare services to its people. Medicines are a key component of a well functioning health care system. In fact, medicines are one of the most cost-effective elements of modern health care. Provision of medicines at an affordable cost in public hospitals and health centres should be the responsibility of governments of every nation of the world. Provision of subsidized essential drugs to all patients accessing public health facilities, while not costing so much to the government, would bring huge savings to the patients, and is the easiest and quickest option to reduce out-of-pocket expenses for the poor [30]. Therefore, public hospital pharmacy should serve as a channel through which majority of Nigerians access medicine free or at a subsidized cost in line with national drug policy that requires government to establish necessary mechanisms to guarantee that drug supply to patients cost less than in the private sector [11].

In compliance with the provision of affordable healthcare, some countries of the world are now providing medicines free to its citizens in the public health care facilities, whereas country like China is selling medicines to patients without mark-ups in the public hospitals. Therefore, since health insurance coverage is still very low in Nigeria, Nigerian government should take a cue from these countries in order to reduce financial burdens posed by high cost of medicines for its citizen.

5. Study Limitations

Health Action International's core drug list was not used because they had few medicines listed for hypertension, and bacterial infections so for studying price variation of such medicines, much detailed listing of commonly used medicines is necessary. The results are not generalizable to the whole country, since the research focused only on a small area.

6. CONCLUSION

This study shows that the prices patients pay for medicines in the public hospital studied were

almost identical to patients' medicine prices in the private retail community pharmacy. This finding has implications for drug accessibility and affordability. Amidst of increase in morbidity of acute and chronic diseases among general population in recent years in Nigeria, the Nigerian government through the ministry of health should play proactive roles to keep the price of medicines at the affordable price in the public hospitals. To be able to do this, measures should be taken to implement the centralized medicine purchasing system through competitive bidding to make medicine procurement efficient and at the same time, regulate mark-ups. Comprehensive medicine pricing policy should be formulated and enforced. This should include monitoring and regulating medicine prices in the public hospitals.

CONSENT

It is not applicable.

ETHICAL APPROVAL

The study protocol was approved by the Research and Ethics Committee of the University of Nigeria Teaching Hospital, Ituku-Ozalla in South Eastern Nigeria.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. MedecinSans Frontieres. Campaign for access to essential medicines; 2017 Available:http://www.ealliance.ch/.../secure19e7.pdf?.../MSF_CampaignAccessEssentialMedicines. [Accessed September 14, 2017]
2. WHO. Equitable access to essential medicines: A framework for collective action. Geneva: World Health Organization; 2004a.
3. Wirtz VJ, Santa-Ana-Tellez Y, Servan-Mori E, Avila-Burgos L. Heterogeneous effects of health insurance on out-of-pocket expenditure on medicines in Mexico. *Value in Health*. 2012;15(5):593-603.
4. Orem JN, Mugisha F, Okui AP, Musango L, Kirigia JM. Health care seeking patterns and determinants of out-of-pocket expenditure for malaria for the children under-five in Uganda. *Malaria Journal*. 2013;12(1):1.
5. World Health Organization. Dept. of essential drugs and medicines policy. The world medicines situation. 2nd ed. Geneva: World Health Organization; 2004b.
6. Garg CC, Karan AK. Reducing out-of-pocket expenditures to reduce poverty: a disaggregated analysis at rural-urban and state level in India. *Health Policy and Planning*. 2009;24(2):116-128.
7. Brinda EM, AndreÃs RA, Enemark U. Correlates of out-of-pocket and catastrophic health expenditures in Tanzania: Results from a national household survey. *BMC International Health and Human Rights*. 2014;14(1):1.
8. Wang Q, Fu AZ, Brenner S, Kalmus O, Banda HT, De Allegri M. Out-of-pocket expenditure on chronic non communicable diseases in sub-Saharan Africa: The case of rural Malawi. *PloS one*. 2015;10(1):e0116897.
9. NieËns LM, Cameron A, Vandepoel E, Ewen M. Al E. Quantifying the impoverishing effects of purchasing medicines: A cross-country comparison of the affordability of medicines in the developing world. *PLoS Medicine*, 2010;7(8):e1000333.
10. World Health Organization, Health Action International. *Medicine prices—a new approach to measurement*. Geneva: World Health Organization; 2003. Available:http://whqlibdoc.who.int/hq/2003/WHO_EDM_PAR_2003.2.pdf. [Accessed September 15, 2017]
11. Federal ministry of health, Nigeria. *National Drug Policy*; 2005. Available:<http://collections.infocollections.org/whocountry/en/d/Js6865e/9.4.html>. [Accessed September 29, 2017]
12. Nigerian health sector market study report. Study commissioned by the Embassy of the Kingdom of the Netherlands in Nigeria; 2015.
13. Federal Ministry of Health (FMoH), 2010-2011, Nigeria. Available:<http://www.fmh.gov.ng/> [Accessed September 29, 2017]
14. Federal Ministry of Health, Nigeria. *Nigeria Pharmaceutical Country Profile*; 2011.
15. *World Development Indicators*; 2004.
16. Duru P. Only 4% of Nigerians covered by NHIS.

- Available:www.vanguardngr.com/2016/12/4-nigerians-covered-nhis/ (Accessed May 24, 2017)
17. Health Action International (HAI). Medicine Prices in Nigeria; Prices people pay for medicines; 2004.
Available:http://www.haiweb.org/medicines/prices/surveys/200409NG/survey_report.pdf [Accessed September 29, 2017]
 18. Ike SO. The pattern of admissions into the medical wards of the University of Nigeria Teaching Hospital, Enugu (2). Niger J Clin Pract. 2008;11(3):185-92.
 19. Federal Ministry of Health, Nigeria. Essential Medicines List. Fifth Edition; 2010.
 20. Mendis S, Fukino K, Cameron A, et al. The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries. Bull World Health Organ. 2007;85(4):279-288.
 21. Ministry of Health Indonesia In collaboration with: WHO Jakarta and Health Action International. The Prices People have to pay for Medicines in Indonesia; 2004–2005.
 22. Mishra SR, Kandel N, Subedi N, Khanal V. Variation in prices of cardiovascular drugs in public and private pharmacies in Nepal. Health Services Research and Managerial Epidemiology. 2015;1-6.
 23. Ministry of Health, Ghana. Medicine prices in Ghana: A comparative study of Public. Private and Mission Sector Medicine Prices; 2004.
 24. Federal democratic republic of ethiopia ministry of health. Survey on prices of medicines in Ethiopia. Addis Ababa, Ethiopia; 2005.
 25. Babar ZUD, Ibrahim MIM, Singh H, Bukahri NI, Creese A. Evaluating drug prices, availability, affordability, and price components: implications for access to drugs in Malaysia. PLoS Med. 2007;4(3):e82.
 26. Health Action International. Medicine Prices, Availability, Affordability and Components in Peru; 2007.
 27. Improving access to affordable medicines in public hospitals – Asian.
Available:<https://www.adb.org/sites/default/files/project-document/174928/49194-001-tar.pdf>. [Accessed September 29, 2017]
 28. Lum M. The rising cost of drugs; 2017.
Available:<http://www.star2.com/health/wellness/2015/09/27/the-rising-cost-of-drugs/>. [Accessed September 29, 2017]
 29. Mohamed Idris SM. High medicine prices are killing patients. The Malaysian Times; 2017.
Available:www.themalaysiantimes.com.my/high-medicine-prices-are-killing-patients/. [Accessed October 01, 2017]
 30. Sharma S, Chaudhury RR. Improving availability and accessibility of medicines: A tool for increasing healthcare coverage. Archives of Medicine. 2015;7(5):12.

© 2018 Okoro and Nmeka; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here:
<http://www.sciencedomain.org/review-history/24885>